Citeline and Norstella announced the completion of their $5 billion merger Tuesday morning.
The deal, first announced in late June, creates one of the world’s largest pharmaceutical intelligence solutions providers. The combined company has $5 billion and 1,600 employees.
Citeline will join four other brands, Evaluate, MMIT, Panalgo and The Dedham Group, as part of Norstella.
The move brings together the capabilities of Citeline (formerly Pharma Intelligence) with Norstella’s end-to-end solutions focused on improving access to life-saving therapies for patients.
“We believe that patient access starts with identifying unmet needs and doesn’t end until a patient has a therapy in hand,” Norstella CEO Mike Gallup said in a statement. “As the industry moves toward highly targeted therapies focused on smaller patient populations, our clients need solutions that provide actionable answers to critical business questions to help bring drugs to market quicker—ultimately helping patients receive treatment sooner.”
Gallup added that the deal seeks to create a “healthcare marketplace that’s more innovative and accessible for all.”
“This union is an opportunity for both Citeline and Norstella to advance their shared mission of making therapies available to the patients who need them,” said Jay Nadler, Executive Chair of Norstella and Citeline CEO Ramsey Hashem, in a statement. “We feel an urgency to make an impact, and we believe that we can bring innovation that will change patients’ lives.”
To read a January 2024 article about Norstella’s Evaluate acquiring J+D Forecasting, click here.
